PHLDB2 and gastric cancer: In this study, we employed RO4929097 to inhibit NOTCH3 both in vitro and in vivo, and found that NOTCH3-ICD and PHLDB2 expression were abrogated after treatment, suggesting GC patients with NOTCH3-PHLDB2 activation might benefit from GSI.